Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839129 | 0.80 | HSD17B10 (0.51) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL19718382 | 0.78 | MEN1 (0.40) | KMT2AMEN1ALDH1A1HSD17B10NUDT1 | |
| SCHEMBL1614004 | 0.77 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1HSD17B10NUDT1 | |
| SCHEMBL23021638 | 0.77 | NUDT1 (0.33) | KMT2AMEN1ALDH1A1NUDT1SMN1; SMN2 | |
| SCHEMBL1421329 | 0.71 | GABRA5 (0.40) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL4911470 | 0.69 | KMT2A (0.39) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL17716400 | 0.69 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17716402 | 0.69 | SCN9A (0.36) | KMT2AMEN1ALDH1A1HSD17B10NUDT1 | |
| SCHEMBL914923 | 0.67 | — | — | |
| SCHEMBL15110981 | 0.67 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121797-A1 | A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION | AUCLAIR, CHRISTIAN (FR) | 2023-04-20 | — | — | US | disclosed |
| WO-2021191336-A1 | A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION | AC BIOSCIENCE SA (CH) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121797-A1 | A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION | SGPL1, SPHK1, S1PR1 | KMT2A 2151/4885MEN1 3667/4885ALDH1A1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.